The global premature ejaculation therapeutics market is estimated to reach revenues of approximately $3 billion by 2024, growing at a CAGR of around 9% during 2018-2024.
The entry of new vendors is leading to high capital investment for R&D activities and manufacturing of new prescription drugs in the global market. The increasing awareness and focus on sexual wellness will create lucrative opportunities for leading vendors operating in the market.The global premature ejaculation therapeutics market is driven by growing patient willingness to seek pharmaceutical therapy assistance for disease management. The launch of off-label drugs belonging to SSRIs and topical formulations will revolutionize the global market over the next few years. The market research report provides in-depth market analysis and segmental analysis of the global premature ejaculation therapeutics market by drug class, ROA, and geography.
The report considers the present scenario of the global premature ejaculation therapeutics market and its market dynamics for the period 2019?2024. It covers a detailed overview of various market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes the leading companies and various other prominent companies operating in the market.
PE is one of the common sexual disorders prevalent in men. Many results from many epidemiological studies, PE is considered to be the most prevalent sexual disorder in men. Globally, the prevalence rate of PE is in the range of 25% to 40% in men across all age groups. As per estimates, the prevalence of PE is more than 20% in regions like Europe, APAC, Latin America, and North America. The Middle East and African regions have a prevalence rate of 13% and 11% respectively. The existence of non-pharmacological treatment modalities, multiple international and regional guidelines recommend the administration of pharmacological agents (alone or in a combination of behavioral techniques/psychological therapy and drug therapy) as the first-line option for the management of the lifelong or acquired PE. The prime factor in the recommendation of drug therapy is its superiority than other non-pharmacological therapies. In addition, many research studies confirmed that therapeutic intervention with various available drugs is effective in improving the signs and symptoms of PE.Pharmaceutical advances are continually leading to the innovation of new drug formulations and drug delivery systems. These advances are improving the efficacy and safety of drugs by enhancing bioavailability, improving drug absorption and modifying the rate of drug release.
This market research report includes a detailed segmentation of the market by drug class, ROA, and geography.The global premature ejaculation therapeutics market by drug class is segmented into SSRIs, PDE5 inhibitors, anesthetic agents, and others. SSRIs segment dominated more than 1/3rd of the total market share in 2018, growing at a CAGR of more than 8% during the forecast period. SSRIs is the most common type of drug for premature ejaculation treatment, and the introduction of Priligy (dapoxetine), which gained regulatory approval in 2009 is fueling the growth of this segment in the global market.Some of the common brand names of PDE5 inhibitors that are available in the global market include Cialis, Viagra, and Levitra. The plethora of unlicensed formulations, comprising anesthetic drugs and anesthetic agents will lead to an increase in clinical trials in the market.
The ROA segment in the global premature ejaculation therapeutics market is classified into oral therapeutics and topical therapeutics. Topical therapeutics is the fastest growing segment in the global market, at a CAGR of over 10% during the forecast period. The continual approval for new topical OTC formulations, rise in product uptake of existing products due to increase in disease awareness, and interest of couples for sexual wellbeing are some of the factors attributing to the growth of this segment in the global market.The daily dose oral therapies can exhibit improved and enhanced efficacy over topical therapies for treating PE. Some of the leading off-label oral formulation brands available in the global premature ejaculation therapeutics market are Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro.
Market Segmentation by Drug Class • SSRIs • PDE5 Inhibitors • Anesthetic Agents • Others
Market Segmentation by ROA • Oral Therapeutics • Topical Therapeutics
The global premature ejaculation therapeutics market by geography is categorized into North America, Europe, APAC, Latin America, and MEA. North America occupied the largest market share in 2018, growing at a CAGR of around 9% during the forecast period. The rising lifestyle-related stress, the rise in chronic conditions, which can lead to the incidence of PE, increases in cancers, especially prostate cancer is fueling the growth of the North American region in the global market.The high disease prevalence population, improvement in healthcare spending, increase in PE awareness, increase in uptake of PE drugs especially the off-label generic medicines, and low-cost OTC drugs are fueling the demand across the APAC region in the global premature ejaculation therapeutics market.
Market Segmentation by Geography • North America o US o Canada • Europe o UK o Germany o France o Italy o Spain • APAC o Japan o India o China o Australia • Latin America o Brazil o Mexico • MEA
Key Vendor Analysis The global premature ejaculation therapeutics market is fairly fragmented due to the presence of pharma companies and generic manufacturers. The top vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents to attract the maximum number of consumers in the global market. The exponential growth of the APAC and Latin American region will create lucrative investment opportunities for prominent players in the market. Factors such as access to drugs, high disease awareness, and high affordability will help companies boost revenues in the global premature ejaculation therapeutics market.
The major vendors in the global market are: • Absorption Pharmaceuticals • INNOVUS PHARMACEUTICALS • Pfizer • Plethora Solutions Holdings
Other prominent vendors include Bayer, Eli Lilly and Company, GlaxoSmithKline, Recordati, Royalty Pharma, The Menarini Group, Ixchelsis.
Key market insights include 1. The analysis of global premature ejaculation therapeutics market provides market size and growth rate for the forecast period 2019-2024. 2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global premature ejaculation therapeutics market. 3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities. 4. It offers a complete overview of market segments and the regional outlook of global premature ejaculation therapeutics market. 5. The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.
Our reports have been used by over 10K customers, including:
Global Immunology Partnering 2014 to 2019 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Immunology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Immunology partnering...
Global Hematology Partnering 2014 to 2019 provides the full collection of Hematology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Hematology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hematology partnering...
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2019 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the...
Arrhythmias - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H1 2019, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape. An arrhythmia is a problem with the rate or...
Central Venous Catheters - Medical Devices Pipeline Assessment, 2019 Summary GlobalData’s Medical Devices sector report, “Central Venous Catheters - Medical Devices Pipeline Assessment, 2019" provides an overview of Central Venous Catheters currently in pipeline stage. The report provides...
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 22.214.171.124) - Pipeline Review, H1 2019 Summary Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 126.96.36.199) pipeline Target constitutes close to 5 molecules....
Blepharitis - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H1 2019, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape. Blepharitis is an inflammation of the eyelids,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.